Green Thumb Industries (GTBIF) Income from Non-Controlling Interests (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Income from Non-Controlling Interests came in at -$350000.0 in Q1 2026, down 468.42% YoY from $95000.0 in Q1 2025, and down 316.67% on a QoQ basis from -$84000.0 in Q4 2025.
Green Thumb Industries (GTBIF) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 8 years of Income from Non-Controlling Interests data on file, last reported at -$350000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 468.42% year-over-year to -$350000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 146.36% YoY) and the FY2025 annual result came in at $1.9 million, up 147.53% from the prior year.
- Income from Non-Controlling Interests eased to -$350000.0 in Q1 2026, from -$84000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $1.4 million in Q2 2025 to a low of -$350000.0 in Q1 2026.
- A 5-year average of $302823.5 and a median of $290000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2025 — Income from Non-Controlling Interests surged 568.45% — and 2026, when it tumbled 468.42%.
- Tracing GTBIF's Income from Non-Controlling Interests over 5 years: stood at $317000.0 in 2022, then declined by 5.05% to $301000.0 in 2023, then plunged by 58.47% to $125000.0 in 2024, then sank by 167.2% to -$84000.0 in 2025, then plunged by 316.67% to -$350000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$350000.0 (Q1 2026), -$84000.0 (Q4 2025), and $513000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Green Thumb Industries | 1.66 Bn | 1.37 Bn | 137.87 Mn | -1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.45 Mn |
| Mar 31, 2026 | -350,000.00 |
| Dec 31, 2025 | -84,000.00 |
| Sep 30, 2025 | 513,000.00 |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 95,000.00 |
| Dec 31, 2024 | 125,000.00 |
| Sep 30, 2024 | 165,000.00 |
| Jun 30, 2024 | 206,000.00 |
| Mar 31, 2024 | 272,000.00 |
| Dec 31, 2023 | 301,000.00 |
| Sep 30, 2023 | 295,000.00 |
| Jun 30, 2023 | 290,000.00 |
| Mar 31, 2023 | 266,000.00 |
| Dec 31, 2022 | 317,000.00 |
| Sep 30, 2022 | 319,000.00 |
| Jun 30, 2022 | 294,000.00 |
| Mar 31, 2022 | 747,000.00 |
| Dec 31, 2021 | 1.24 Mn |
| Sep 30, 2021 | 1.38 Mn |